Igzelym

Ticagrelor, the active ingredient in Igzelym, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It reduces thrombotic cardiovascular events in patients with acute coronary syndrome and helps prevent atherothrombotic events in those with a history of myocardial infarction.

GNH USA supplies Igzelym as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ticagrelor acts on platelet aggregation pathways to lower the risk of cardiovascular events. It is indicated for the following conditions: - Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke. - History of myocardial infarction: lowers the incidence of recurrent atherothrombotic events. - Patients undergoing percutaneous coronary intervention: helps prevent stent thrombosis and related complications.

Ticagrelor may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dyspnea: shortness of breath occurring in many patients. - Bleeding: including bruising, epistaxis or gastrointestinal bleeding. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Dizziness: transient light‑headedness. - Hypotension: occasional drop in blood pressure.

Serious or Rare Side Effects: - Severe bleeding: life‑threatening hemorrhage such as intracranial bleeding. - Allergic reactions: rash, pruritus, or anaphylaxis. - Thrombocytopenia: marked reduction in platelet count. - Myocardial infarction recurrence: rare cases of worsening ischemia. - Hepatic injury: elevated liver enzymes in susceptible individuals.

Before prescribing Ticagrelor, clinicians should consider several safety measures. - Assess bleeding risk: review patient history for active or recent bleeding. - Monitor renal function: adjust therapy in severe renal impairment. - Avoid in active pathological bleeding: discontinue if uncontrolled hemorrhage occurs. - Caution with concomitant anticoagulants: increased risk of major bleeding. - Store at room temperature: keep in the original pack, protect from moisture.

Ticagrelor can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor exposure and bleeding risk. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding potential.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal bleeding risk. - SSRIs or SNRIs: may increase bleeding tendency. - Statins metabolised by CYP3A4 (e.g., simvastatin): monitor for possible increased plasma levels.